摘要
目的:探讨米非司酮对围绝经期子宫腺肌病的临床疗效以及长疗程、小剂量使用的安全性。方法:回顾性分析我院41例围绝经期子宫腺肌病患者的临床资料,均于月经第5天开始口服米非司酮10mg,日服1次,连续服用12个月,分别于服药前、服药3、6、9、12个月测定血色素、肝肾功能、CA125、性激素六项、血糖及血脂的变化;B超动态观察腺肌瘤大小、子宫体积的变化;观察体重及临床症状、毒副作用发生的情况。结果:服药后子宫腺肌瘤的体积和子宫体积均缩小,贫血者全部纠正,性激素中促卵泡激素(FSH)、黄体生成素(LH)、雌二醇(E2)及孕酮(P)下降,睾酮(T)上升;均有显著性差异(P<0.05);临床症状减轻或消失,血脂有升高趋势,但无显著性差异(P>0.05);CA125全部降至正常。服药12个月后,有7例患者出现转氨酶升高。结论:长疗程、小剂量米非司酮治疗围绝经期子宫腺肌病疗效显著,子宫及腺肌瘤明显缩小、痛经消失以至绝经,但长期服用血脂有升高趋势,部分患者出现转氨酶升高,故长期用药需注意肝功能的影响及对血脂代谢的观察。
Objective： To explore the clinical effect and safety of long period and low dosage Mifepristone in the treatment of perimenopausal uterine adnomyosis. Methods： Forty one patients were given Mifepristone 10 mg/d for 12 months beginning on the fifth day of the menstrual cycle by retrospection analysis. The hemoglobin, liver and kidney function, CA125, six indexes of sex hormone, blood sugar and lipids were recorded at 0, 3, 6, 9, 12 months after treatment respectively; the volume of uterine leiomyomata and the uterus were observed by B-utrasound; the weight, clinical symptom and the toxic and adverse reaction were recorded. Results： The volume of both uterine leiomyomata and the uterus were dwindled, all the anemia patients were normal, the FSH, LH, E2 and P were reduced and T was risen （P〈0.05）; clinical symptoms were disappeared or alleviated; lipids had an uptrend （P〉0.05）; all the CA125 became normal. 12 months after treatment, seven patients＇ anfinotransferase had risen. Conclusion： The clinical effect of long period and low dosage Mifepristone in the treatment of perimenopausal uterine adnomyosis is obvious. It can shrink the volume of uterine leiomyomata and the uterus, the dysmenorrheal disappears or menopause is found. But lipid has an uptrend, some patients＇ aminotransferase has risen, thus the liver function and the lipids must be observed carefully after long period Mifepristone in the treatment.
出处
《中国医药导报》
CAS
2009年第10期18-20,共3页
China Medical Herald
